Adjuvants and lymphoma risk as part of the ASIA spectrum

National Institutes of Health USA.gov. Understanding autoimmune diseases. October-2012. http://www.niams.nih.gov/HEALTH_INFO/Autoimmune/understanding_autoimmune.pdf. Kapatai G, Murray P. Contribution of the Epstein–Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol. 2007;60(12):1342–9. Shehab TM, Hsi ED, Poterucha JJ, Gunaratnam NT, Fontana RJ. Helicobacter pylori-associated gastric MALT lymphoma in liver transplant recipients. Transplantation. 2001;71:1172–5. Sagaert X, Van Cutsem E, De Hertogh G, Geboes K, Tousseyn T. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol. 2010;7(6):336–46. Mariette X. Lymphomas complicating Sjögren’s syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis. 2001;60:1007–10. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130–5. Shoenfeld Y, Agmon-Levin N. ‘ASIA’—autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8. Schaefer CJ, Lawrence WD, Wooley PH. Influence of long term silicone implantation on type II collagen induced arthritis in mice. Ann Rheum Dis. 1999;58:503–9. Koppang EO, Bjerkås I, Haugarvoll E. Vaccination-induced systemic autoimmunity in farmed Atlantic salmon. J Immunol. 2008;181(7):4807–14. Schaefer CJ, Wooley PH. The influence of silicone implantation on murine lupus in MRL lpr/lpr mice. J Rheumatol. 1999;26(10):2215–21. Dimitrijević L, Živković I, Stojanović M, et al. Vaccine model of antiphospholipid syndrome induced by tetanus vaccine. Lupus. 2012;21:195–202. Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (auto-inflammatory) syndrome induced by adjuvants’. Lupus. 2012;21(2):118–20. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1–16. Malik AF, Hoque R, Ouyang X. Inflammasome components Asc and caspase-1 mediate biomaterial-induced inflammation and foreign body response. Proc Natl Acad Sci USA. 2011;108(50):20095–100. Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32:114–20. Bichel L. Postvaccinial lymphadenitis developing into Hodgkin’s disease. Acta Med Scand. 1976;199(6):523–5. Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol. 2005;52(4):623–9. Hernández I, Sanmartín O, Cardá C, Góme S, Alfaro A. B-cell pseudolymphoma caused by aluminium hydroxide following hyposensitization therapy. Actas Dermosifiliogr. 2008;99(3):213–6. Codrich D, Monai M, Pelizzo G, et al. Primary pulmonary Hodgkin’s disease and tuberculosis in an 11-year-old boy: case report and review of the literature. Pediatr Pulmonol. 2006;41(7):694–8. Sanchez-Gonzalez B, Garcia M, Montserrat F, et al. Diffuse large B-cell lymphoma associated with chronic inflammation in metallic implant. J Clin Oncol. 2013;31(10):e148–51. Chaudhry MS, Mather H, Marks A, Naresh K. Diffuse large B cell lymphoma complicating total knee arthroplasty: case report and literature review of the association of diffuse large B cell lymphoma with joint replacement. Acta Haematol. 2011;126(3):141–6. Cheuk W, Chan AC, Chan JK, Lau GT, Chan VN, Yiu HH. Metallic implant-associated lymphoma: a distinct subgroup of large B-cell lymphoma related to pyothorax-associated lymphoma? Am J Surg Pathol. 2005;29(6):832–6. Lidgren L. Chronic inflammation, joint replacement and malignant lymphoma. J Bone Joint Surg Br. 2008;90(1):7–10. Madewell BR, Gieger TL, Pesavento PA, Kent MS. Vaccine site-associated sarcoma and malignant lymphoma in cats: a report of six cases (1997–2002). J Am Anim Hosp Assoc. 2004;40:47–50. Anderson PN, Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature. 1969;222(5197):994–5. Potter M. A resumé of the current status of the development of plasma-cell tumors in mice. Cancer Res. 1968;28:1891–6. Wooley PH, Whalen JD. Pristane-induced arthritis in mice. III. Lymphocyte phenotypic and functional abnormalities precede the development of pristane-induced arthritis. Cell Immunol. 1991;138(1):251–9. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother. 2004;58:325–37. Kojima M, Itoh H, Shimizu K, et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int J Surg Pathol. 2006;14(1):43–8. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders—What are the driving forces? Semin Cancer Biol. 2014;24:61–70. Bichile T, Petri M. Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. Curr Opin Rheumatol. 2014;26(2):111–7. Tarella C, Gueli A, Ruella M, Cignetti A. Lymphocyte transformation and autoimmune disorders. Autoimmun Rev. 2013;12(8):802–13. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796–803. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomark Prev. 2006;15(11):2069–77. Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren’s syndrome patients. Clin Rev Allergy Immunol. 2007;32(3):265–74. Routsias JG, Goules JD, Charalampakis G, Tzima S, Papageorgiou A, Voulgarelis M. Malignant lymphoma in primary Sjögren’s syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum. 2013;43(2):178–86. Kristinsson SY, Landgren O, Sjöberg J, Turesson I, Björkholm M, Goldin LR. Autoimmunity and risk for Hodgkin’s lymphoma by subtype. Haematologica. 2009;94(10):1468–9. Van Baarsen LG, de Hair MJ, Ramwadhdoebe TH, et al. The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis. Ann Rheum Dis. 2013;72(8):1420–4. Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med Insights Ther. 2010;2:749–60. Sluzevich JC, Hall MR, Roy V. Subcutaneous panniculitis-like T-cell lymphoma after rituximab. J Am Acad Dermatol. 2012;67(5):e223–5. Blank M, Gershwin ME. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun. 2008;30(1–2):1–4. Anaya JM, Corena R, Castiblanco J, Rojas-Villarraga A, Shoenfeld Y. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol. 2007;3(4):623–35. Gherardi RK. Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. Rev Neurol (Paris). 2003;159(2):162–4. Han S, Asoyan A, Rabenstein H, Nakano N, Obst R. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci USA. 2010;107(47):20453–8. Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670–84. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205(8):1797–805. Kappel R, Cohen Tervaert J, Pruijn G. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) due to silicone implant incompatibility syndrome in three sisters. Clin Exp Rheumatol. 2014;32(2):256–8. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22(2):223–30. Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT. Cancer risk in patients with chronic urticaria: a population-based cohort study. 35. Arch Dermatol. 2012;148(1):103–8. Jafroodi M, Zargari O, Hoda S. Concomitant Hodgkin’s lymphoma and atopic dermatitis in a child with Celiac disease. Arch Iran Med. 2009;12(3):317–9. Vu J, Ho J, English JC 3rd. Dermal hypersensitivity reaction as a prodrome to Hodgkin lymphoma. J Am Acad Dermatol. 2010;63(1):e13–4. Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009;123(5):1111-6, 116.e1-13. Vajdic CM, Falster MO, de Sanjose S, et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res. 2009;69(16):6482–9. Porto DA, Comfere NI, Myers LM, Abbott JJ. Pseudolymphomatous reaction to varicella zoster virus vaccination: role of viral in situ hybridization. J Cutan Pathol. 2010;37(10):1098–102. Cerroni L, Borroni RG, Massone C, Chott A, Kerl H. Cutaneous B-cell pseudolymphoma at the site of vaccination. Am J Dermatopathol. 2007;29(6):538–42. Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122–6. Coleman DL, King RN, Andrade JD. The foreign body reaction: a chronic inflammatory response. J Biomed Mater Res. 1974;8(5):199–211. Pan SY, Lavigne E, Holowaty EJ, et al. Canadian breast implant cohort: extended follow-up of cancer incidence. Int J Cancer. 2012;131:E1148–57. Friis S, Hölmich LR, McLaughlin JK, et al. Cancer risk among Danish women with cosmetic breast implants. Int J Cancer. 2006;118:998–1003. Brisson J, Holowaty EJ, Villeneuve PJ, et al. Cancer incidence in a cohort of Ontario and Quebec women having bilateral breast augmentation. Int J Cancer. 2006;118:2854–62. US Food and Drug Administration: Anaplastic large cell lymphoma (ALCL) in women with breast implants: Preliminary FDA findings and analyses. 2013. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239995.htm. Supersaxo A, Hein WR, Steffen H. Mixed micelles as a proliposomal, lymphotropic drug carrier. Pharm Res. 1991;8(10):1286–91. Charman WN. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci. 2000;89(8):967–78. Kadir F. Intramuscular and subcutaneous drug delivery: encapsulation in liposomes and other methods to manipulate drug availability. Pharm World Sci. 1993;15(4):173–5. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18(13):1217–25. Flach TL, Ng G, Hari A. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011;17(4):479–87. Mbow ML, de Gregorio E, Ulmer JB. Alum’s adjuvant action: grease is the word. Nat Med. 2011;17:415–6. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine. 2006;24(Suppl 2):S2-26–9. Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: Are they safe? Curr Med Chem. 2011;18(17):2630–7. Chen L, Zhang B, Toborek M. Autophagy is involved in nanoalumina-induced cerebrovascular toxicity. Nanomedicine. 2013;9(2):212–21. Chen L, Yokel RA, Hennig B, Toborek M. Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature. J Neuroimmune Pharmacol. 2008;3(4):286–95. Marichal T, Ohata K, Bedoret D, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011;17(8):996–1002. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287–93. Martínez-Estévez M, Racagni-Di Palma G, Muñoz-Sánchez JA, Brito-Argáez L, Loyola-Vargas VM, Hernández-Sotomayor SM. Aluminium differentially modifies lipid metabolism from the phosphoinositide pathway in Coffea arabica cells. J Plant Physiol. 2003;160(11):1297–303. Robinson WH, Sokolove J. Citrullination of fibrinogen: generation of neoepitopes and enhancement of immunostimulatory properties. Arthritis Res Ther. 2012;14(Suppl 1):O30. Fredman P, Lekman A. Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders. Neurochem Res. 1997;22(8):1071–83. Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y. Guillain–Barré syndrome—a classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol. 2012;42(2):121–30. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev. 2005;18(1):81–101. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:488–96. Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001;70(6):849–60. Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA. 2008;105(30):10501–6. Butler NR, Voyce MA, Burland WL, Hilton ML. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br Med J. 1969;1(5645):663–6. O’Lenick T, O’Lenick T. Altering organic oils with silicones. H&PC Today. 2011;6(1):72–5. Vera-Lastra O, Medina G, del Pilar Cruz-Dominguez M, et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld’s syndrome). Lupus. 2012;21:128e35. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol. 2006;208:261–9. Blum A, Abboud W, Shajrawi I, Tatour I. Prolonged fever due to silicone granulomatosis. Isr Med Assoc J. 2007;9(2):121–2. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124(Pt 9):1821–31. Krewski D, Yokel RA, Nieboer E, et al. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev. 2007;10(Suppl 1):1–269. Tomljenovic L. Aluminum and Alzheimer’s disease: after a century of controversy, is there a plausible link? J Alzheimers Dis. 2011;23(4):567–98. www.trianglecc.com/labels/Tricard%20Silicone20100%20Label.pdf. Nagase H, Ose Y, Sato T. Possible methylation of inorganic mercury by silicones in the environment. Environ Sci Total Environ. 1988;73(1–2):29–38. Andrews JM. Cellular behavior to injected silicone fluid: a preliminary report. Plast Reconstr Surg. 1966;38(6):581–3. Hu D, Wan L, Chen M, Caudle Y, LeSage G, Li Q, Yin D. Essential role of IL-10/STAT3 in chronic stress-induced immune suppression. Brain Behav Immun. 2014;36:118–27. Kleinewietfeld M, Hafler DA. Regulatory T cells in autoimmune neuroinflammation. Immunol Rev. 2014;259(1):231–44. Elefsiniotis IS, Papatsimpas G, Liatsos GD, Tasidou A, Moulakakis A. Atypical autoimmune polyglandular syndrome type 3 overlapped by chronic HCV infection resulting in carcinogenesis and fatal infection. South Med J. 2008;101(7):756–8. Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive CD21−/low B cells in Sjögren’s syndrome—associated lymphoproliferation. Arthritis Rheum. 2013;65:1085–96. Kauppi M, Pukkala E, Isomäki H. Elevated incidence of hematologic malignancies in patients with Sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control. 1997;8(2):201–4. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011;63:3032–7. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45. Mercer LK, Davies R, Galloway J, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford). 2013;52:91–8. Grainge MJ, West J, Solaymani-Dodaran M, Card TR, Logan RF. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther. 2012;35(6):730–9. Smedby KE, Åkerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut. 2005;54(1):54–9. Zhang JQ, Wan YN, Peng WJ, et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol. 2013;37(5):523–7.